Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1999
Business Overview: Regeneron is a biopharmaceutical company focused on discovering and developing therapeutic drugs for serious medical conditions, including obesity, rheumatoid arthritis, cancer, and neurodegenerative diseases. The company utilizes proprietary technology platforms (Targeted Genomics, Functionomics, and Designer Protein Therapeutics) to identify and engineer drug candidates. As of the reporting date, Regeneron had no commercial product sales and relied on collaboration agreements and contract manufacturing for revenue.
Key Financial Metrics
| Metric (in thousands) | 1999 | 1998 |
|---|---|---|
| Total Revenues | $39,706 | $45,193 |
| Net Loss | ($23,070) | ($8,625) |
| Net Loss Per Share (Basic/Diluted) | ($0.74) | ($0.28) |
| Cash, Cash Equivalents, and Marketable Securities | $93,599 | $113,530 |
| Working Capital | $59,725 | $83,499 |
| Accumulated Deficit | ($200,303) | ($177,233) |
| Long-Term Debt (Capital Leases & Notes) | $2,731 | $3,066 |
Revenue Breakdown (1999):
- Contract research and development: $24.5 million
- Contract manufacturing (Merck): $10.0 million
- Investment income: $5.2 million
- Research progress payments: $0 (Non-recurring payments of $9.5 million occurred in 1998)
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 12% to $39.7 million in 1999 from $45.2 million in 1998. This was primarily due to the absence of non-recurring research progress payments ($9.5 million in 1998) and lower investment income, which were not fully offset by increases in contract research and manufacturing revenue.
- Increased Losses: Net loss widened significantly to $23.1 million in 1999 from $8.6 million in 1998. This was driven by a 21% increase in Research and Development (R&D) expenses to $44.9 million and a higher loss from the Amgen-Regeneron Partners partnership ($4.2 million vs. $2.5 million).
- Strategic Shift in AXOKINE: In the third quarter of 1999, Procter & Gamble (P&G) returned product rights for AXOKINE (an obesity drug candidate) to Regeneron following a Phase I safety study. While P&G ceased funding for AXOKINE specifically, the broader collaboration agreement remained intact, with quarterly research support increasing from $1.1 million to $7.0 million starting in Q3 1999.
- Manufacturing Milestone: Regeneron received FDA approval in December 1999 to manufacture an intermediate for a Merck pediatric vaccine, commencing commercial production and capitalizing manufacturing costs into inventory rather than expensing them.
Guidance, Outlook, and Risks
Outlook and Pipeline:
- AXOKINE: Regeneron plans to initiate a Phase II dose-ranging trial for obesity in March 2000 following the return of rights from P&G.
- Cytokine Traps & VEGF Trap: At least one Cytokine Trap (for rheumatoid arthritis/inflammation) and the VEGF Trap (for cancer) are expected to enter clinical trials by 2001.
- BDNF & NT-3: Clinical trials continue for ALS (BDNF) and constipation (NT-3) via the Amgen-Regeneron Partners partnership.
Liquidity and Capital Resources:
- The company held $93.6 million in cash and marketable securities as of December 31, 1999.
- Management believes existing capital resources will meet operating needs for several years.
- Future funding requirements are expected to increase due to expanded clinical trials and capital contributions to the Amgen-Regeneron partnership (estimated at least $4.5 million for 2000).
Key Risks and Contingencies:
- Commercialization Risk: The company has never sold a commercial product and may never achieve profitability. Success depends on regulatory approval and clinical efficacy.
- Collaboration Dependency: Revenue is heavily dependent on agreements with P&G, Amgen, Sumitomo, and Merck. Termination of these agreements could materially impact operations.
- Regulatory and Clinical Risks: Clinical trials may fail due to safety issues (e.g., antibody formation, adverse events like herpes reactivation observed in AXOKINE trials) or lack of efficacy.
- Intellectual Property: The company is involved in patent interference proceedings regarding CNTF/AXOKINE with Amgen (resolved via a covenant not to sue in 1998), but patent validity remains uncertain.
Investor Verification Checklist
- AXOKINE Phase II Timing: Verify the initiation and progress of the Phase II obesity trial scheduled for March 2000.
- P&G Collaboration Status: Confirm the continued flow of research funding from P&G under the expanded agreement, excluding AXOKINE-specific milestones.
- Merck Manufacturing Revenue: Monitor the recognition of contract manufacturing revenue from the Merck vaccine intermediate agreement, which began commercial production in late 1999.
- Amgen-Regeneron Partnership Costs: Track capital contribution requirements for the partnership, which incurred a $4.2 million loss in 1999 and requires equal funding from Regeneron.
- Cash Burn Rate: Assess the sustainability of the $93.6 million cash position against rising R&D expenses and partnership obligations.